All In Biotech

Free tool

FAERS Monitor: Nucala

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125526 or its brand name (Nucala, Mepolizumab). Reports on generic versions are filed under their own applications.

Reports

50,431

Serious

31,676

63% of reports

Hospitalization

16,281

Death reported

4,180

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • asthma12,892
  • dyspnoea10,717
  • wheezing7,204
  • product dose omission issue6,869
  • cough5,147
  • therapeutic product effect incomplete5,092
  • drug ineffective4,736
  • pneumonia4,726
  • loss of personal independence in daily activities4,281
  • fatigue3,151
  • sleep disorder due to a general medical condition3,148
  • off label use3,137
  • malaise2,828
  • condition aggravated2,813
  • headache2,774

Reports by year received

View as table
YearReports
20081
20092
20121
20135
20147
201518
2016579
20171,547
20183,014
20194,612
20205,676
20216,089
20224,725
20235,642
20247,767
20257,636
20263,110

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,003,728 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
sleep disorder due to a general medical conditionSignal3,14894.791.1237,796
wheezingSignal7,20457.556.2352,509
asthmaSignal12,89253.652.7592,388
loss of personal independence in daily activitiesSignal4,28140.739.5151,350
therapeutic product effect incompleteSignal5,09232.131.2142,797
product dose omission issueSignal6,86910.09.754,772
dyspnoeaSignal10,7178.07.966,478
coughSignal5,1477.87.630,245
pneumoniaSignal4,7266.26.020,454
condition aggravatedSignal2,8133.93.76,057
malaiseSignal2,8282.72.63,070
headache2,7741.81.81,109
fatigue3,1511.71.6919
drug ineffective4,7361.51.5840
off label use3,1371.51.4536

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.